disodium;5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: disodium;5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate
• 化学式: C20H18ClNNa2O7
• 分子量: 465.8
• InChiKey: FUZBPOHHSBDTJQ-CFOQQKEYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -6.43
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  131
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  (R,R)-5-(2-(5-(3-chlorophenyl)-2-oxo-3-oxazolidinyl)propyl)-1,3-benzodioxole-2,2-dicarboxylic acid, diethyl ester 以85的产率得到disodium;5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate
  参考文献：
  名称：

  J. Med. Chem. 1992, 35, 3081-3084

  摘要：

  DOI：

文献信息

• Processes for producing optically active 2-amino-1-phenylethanol derivatives
  申请人：Daicel Chemical Industries, Ltd.

  公开号：US20030143701A1

  公开（公告）日：2003-07-31

  An (R)-2-amino-1-phenylethanol derivative shown by the general formula (IIa) 1 wherein R 1 and R 5 represent a hydrogen atom, etc.; R 2 , R 3 and R 4 independently represent a halogen atom, etc., or a salt thereof, can readily be produced (1) by permitting a microorganism belonging to the genus Rhodosporidium, the genus Comamonas or the like to act on a mixture of corresponding (R)-form and (S)-form to asymmetrically utilize, or (2) by permitting a microorganism belonging to the genus Lodderomyces, the genus Pilimelia or the like to act on a corresponding aminoketone derivative to asymmetrically reduce. An (R,R)-1-phenyl-2-[(2-phenyl-1-alkylethyl)amino]ethanol derivative having a high optical purity can easily be obtained from the compound of the formula (IIa) or a salt thereof. Said derivative is useful as an intermediate for producing an anti-obesity agent and so on.

  通式（IIa）所示的（R）-2-氨基-1-苯乙醇衍生物，其中R1和R5代表氢原子等；R2、R3和R4分别独立地表示卤素原子等，或其盐，可以通过（1）让属于红孢霉属、普通小杆菌属或类似菌属的微生物作用于相应（R）-型和（S）-型的混合物以不对称利用，或（2）让属于洛德罗霉属、皮利米利亚属或类似菌属的微生物作用于相应的氨基酮衍生物以不对称还原而轻松制备。可以从式（IIa）化合物或其盐中轻松获得具有高光学纯度的（R，R）-1-苯基-2-［（2-苯基-1-烷基乙基）氨基］乙醇衍生物。所述衍生物可用作生产抗肥胖剂等中间体。
• Slimming Skin External Preparation and Cosmetic Containing the Same
  申请人：Shibuya Akira

  公开号：US20070232698A1

  公开（公告）日：2007-10-04

  The invention provides a slimming skin external preparation and a cosmetic that contain a carnitine derivative having excellent skin affinity and percutaneous absorption properties and capable of enhancing the fat metabolism, and that can treat, reduce or prevent the obesity by functioning as a lipolytic agent to enhance the fat metabolism of general or local subcutaneous fat tissues. The slimming skin external preparation contains a particular carnitine derivative and preferably other slimming and skin-care ingredients.

  该发明提供了一种含有卡尼汀衍生物的减肥皮肤外用制剂和化妆品，该衍生物具有优异的皮肤亲和性和经皮吸收性能，并能够增强脂肪代谢，通过作为脂肪分解剂增强一般或局部皮下脂肪组织的脂肪代谢，从而能够治疗、减少或预防肥胖。该减肥皮肤外用制剂含有特定的卡尼汀衍生物，最好还包含其他减肥和护肤成分。
• Pharmazeutische Zusammensetzung aus einem beta-3-Adrenozeptor-Agonisten und einem Serotonin- und/oder Norepinephrin-Reuptake-Inhibitor
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP1640000A2

  公开（公告）日：2006-03-29

  Diese Erfindung beschreibt eine neue Kombination für die Behandlung von Blasenfunktionsstörungen, welche einen Serotonin und/oder Norepinephrin Reuptake-Inhibitor und einen beta-3-Adrenozeptor-Agonisten umfasst.

  本发明描述了一种治疗膀胱功能障碍的新型组合物，该组合物由一种血清素和/或去甲肾上腺素再摄取抑制剂和一种β-3-肾上腺素受体激动剂组成。
• Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist
  申请人：Serenity Pharmaceuticals, LLC

  公开号：US10568927B2

  公开（公告）日：2020-02-25

  The invention provides methods and compositions for use of desmopressin in combination with a beta-3-adrenergic receptor agonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.

  本发明提供了去氨加压素与β-3-肾上腺素能受体激动剂联合使用的方法和组合物。这些方法和组合物可用于治疗夜尿症和其他尿频疾病。
• Methods and materials for determining pain sensitivity and predicting and treating related disorders
  申请人：The University of North Carolina at Chapel Hill

  公开号：US11085081B2

  公开（公告）日：2021-08-10

  Methods of treating somatosensory disorders and modulating production of proinflammatory cytokines by administering to a subject an effective amount of a COMT modulator, ADRB2 modulator, ADRB3 modulator or combinations thereof are provided. Methods of predicting effective pharmacological therapies for a subject afflicted with a somatosensory disorder by determining a genotype of the subject with regard to a gene selected from the group consisting of COMT, ADRB2, ADRB3, and combinations thereof are further provided. Methods of determining pain responses or pain perception and predicting susceptibility of a subject to develop related disorders, such as somatosensory disorders and somatization, by determining a genotype of the subject with regard to a gene selected from the group consisting of COMT, ADRB2, ADRB3, and combinations thereof are further provided.

  提供了通过向受试者施用有效量的 COMT 调节剂、ADRB2 调节剂、ADRB3 调节剂或其组合来治疗躯体感觉障碍和调节促炎细胞因子产生的方法。还提供了通过确定受试者选自 COMT、ADRB2、ADRB3 及其组合组成的组的基因的基因型来预测患有躯体感觉障碍的受试者的有效药物疗法的方法。还提供了通过确定受试者选自 COMT、ADRB2、ADRB3 及其组合组成的组的基因的基因型来确定疼痛反应或疼痛感知以及预测受试者患相关疾病（如躯体感觉障碍和躯体化）的易感性的方法。